Literature DB >> 1711067

Expression and functional characterization of a soluble form of endothelial-leukocyte adhesion molecule 1.

R R Lobb1, G Chi-Rosso, D R Leone, M D Rosa, S Bixler, B M Newman, S Luhowskyj, C D Benjamin, I G Dougas, S E Goelz.   

Abstract

Endothelial leukocyte adhesion molecule 1 (ELAM1) is a leukocyte adhesion molecule induced on human venular endothelium in vitro and in vivo by inflammatory stimuli. A truncated cDNA for ELAM1 has been constructed, stably expressed in Chinese hamster ovary cells, and the secreted recombinant soluble form of ELAM1 (rsELAM1) purified to homogeneity by immunoaffinity chromatography. rsELAM1, when immobilized on plastic, is fully functional as an adhesion protein, and selectively binds only cells known to bind cell-surface ELAM1 expressed on human endothelial cells, including the myelomonocytic cell line HL60 and the colon carcinoma cell line HT29. Immobilized rsELAM1 also binds human PMN, monocytes, NK cells, and T cells. T cell subset analyses indicate preferential binding of CD4+ T memory cells. However, rsELAM1 is only a weak inhibitor of ELAM1-mediated adhesion. rsELAM1 should prove valuable for the further study of the role of ELAM1 expressed on the vascular wall during the inflammatory response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711067

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  A direct comparison of selectin-mediated transient, adhesive events using high temporal resolution.

Authors:  M J Smith; E L Berg; M B Lawrence
Journal:  Biophys J       Date:  1999-12       Impact factor: 4.033

2.  Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease.

Authors:  M Göke; J C Hoffmann; J Evers; H Krüger; M P Manns
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

3.  The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow.

Authors:  A Peled; V Grabovsky; L Habler; J Sandbank; F Arenzana-Seisdedos; I Petit; H Ben-Hur; T Lapidot; R Alon
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 4.  Immunoaffinity chromatography.

Authors:  G W Jack
Journal:  Mol Biotechnol       Date:  1994-02       Impact factor: 2.695

5.  Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody.

Authors:  D K Podolsky; R Lobb; N King; C D Benjamin; B Pepinsky; P Sehgal; M deBeaumont
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

6.  Transient endotoxemia during burn wound revision causes leukocyte beta 2 integrin up-regulation and cytokine release.

Authors:  O Ljunghusen; S Berg; J Hed; J Lundahl; H Nettelblad; F Sjögren; O Stendahl
Journal:  Inflammation       Date:  1995-08       Impact factor: 4.092

7.  Circulating adhesion molecules in the critically ill: a comparison between trauma and sepsis patients.

Authors:  J Boldt; M Muller; D Kuhn; L C Linke; G Hempelmann
Journal:  Intensive Care Med       Date:  1996-02       Impact factor: 17.440

8.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro.

Authors:  J F Leeuwenberg; E F Smeets; J J Neefjes; M A Shaffer; T Cinek; T M Jeunhomme; T J Ahern; W A Buurman
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

9.  Expression of endothelial adhesion molecules in vivo. Increased endothelial ICAM-2 expression in lymphoid malignancies.

Authors:  R Renkonen; T Paavonen; P Nortamo; C G Gahmberg
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

10.  Increased binding of synovial T lymphocytes from rheumatoid arthritis to endothelial-leukocyte adhesion molecule-1 (ELAM-1) and vascular cell adhesion molecule-1 (VCAM-1).

Authors:  A A Postigo; R Garcia-Vicuña; F Diaz-Gonzalez; A G Arroyo; M O De Landázuri; G Chi-Rosso; R R Lobb; A Laffon; F Sánchez-Madrid
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.